SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 428-431. Prepublished online as a Blood First Edition Paper on August 26, 2004; DOI 10.1182/blood-2004-01-0371. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0371v1 105/1/428    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gendelman, M. Articles by Drobyski, W. R. Search for Related Content PubMed PubMed Citation Articles by Gendelman, M. Articles by Drobyski, W. R. Related Collections Transplantation Immunotherapy Brief Reports Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief report Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration Maria Gendelman, Nadine Halligan, Richard Komorowski, Brent Logan, William J. Murphy, Bruce R. Blazar, Kirkwood A. Pritchard, Jr, and William R. Drobyski From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN. Administration of agonistic monoclonal antibodies or recombinant cytokines is a potential approach to enhance antitumor immunity in bone marrow (BM) transplant recipients, but is complicated by toxicity due to proinflammatory cytokine-mediated vital organ damage. We used a murine syngeneic bone marrow transplant (BMT) model, in which administration of anti-CD40 antibody early after BMT results in overproduction of interleukin-12 (IL-12) and interferon- (IFN-), and lethal gut toxicity to examine the protective effect of the spin trap inhibitor, alpha phenyl-tert-butyl nitrone (PBN). Administration of PBN protected transplant recipients from mortality by significantly attenuating gut toxicity, but did not effect a reduction in the levels of proinflammatory cytokines (IL-12, IFN-, tumor necrosis factor [TNF-], or nitrate/nitrite). Moreover, PBN did not compromise anti-CD40 antibody-mediated antitumor effects in a nontransplantation lymphoma model. Collectively, these data suggest that PBN administration may represent a novel approach for reduction of toxicity without compromise of antitumor effects resulting from administration of therapeutic antibodies in both transplantation and nontransplantation settings. (Blood. 2005;105:428-431) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. R. French, V. Y. Taraban, G. R. Crowther, T. F. Rowley, J. C. Gray, P. W. Johnson, A. L. Tutt, A. Al-Shamkhani, and M. J. Glennie Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation Blood, June 1, 2007; 109(11): 4810 - 4815. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020